



# DOX and induced cardiotoxicity

## DOX's damage

Ezhar Korkmaz Ersöz<sup>1</sup>, Yasemin Hacanlı<sup>1</sup>

<sup>1</sup>Department of Cardiovascular Surgery, Faculty of Medicine, Harran University, Şanlıurfa, Türkiye.

### Abstract

Cancer, one of the most important and deadly diseases of our age, is very difficult to treat. The toxic effects of the drugs used affect the antineoplastic treatment. Anthracyclines are substances that have been proven to be beneficial in cancer chemotherapy in research on microbial products. Doxorubicin is one of the chemotherapeutic agents used in cancer treatment. A broad-spectrum anthracycline is known to have beneficial effects such as antibiotics, as well as adverse effects such as cardiac damage. Doxorubicin causes reactive oxygen radicals in the cell. Today, new natural antioxidant sources are of great importance because of the importance of using antioxidant molecules in the treatment of diseases caused by free radicals. Therefore, it has been shown that the use of antioxidants may be protective against oxidative stress caused by doxorubicin and other cytotoxic drugs. Due to the antioxidant properties of *Pistacia vera* L. (P. v. L.), which has a high phenolic content, it has been shown in various studies that it is beneficial in anti-inflammatory activity, glycemic control and protection of endothelial function and prevents low oxidation.

### Keywords

cancer, DOX, cardiotoxicity, oxidative stress, antioxidant

DOI:10.4328/ECAM.10044

Received : 2022-09-23

Accepted : 2022-10-11

Published Online : 2022-10-11

Printed : 2022-09-01

**Eu Clin Anal Med 2022;10(3):34-37**

**Corresponding Author:** Ezhar Korkmaz Ersöz, Department of Cardiovascular Surgery, Faculty of Medicine, Harran University, Şanlıurfa, Türkiye.

**P.:** +90 505 707 61 90 - **Email:** ezharkorkmaz@hotmail.com - **Corresponding Author ORCID ID:** <https://orcid.org/0000-0002-7531-4958>

## Introduction

Doxorubicin (DOX) is the hydroxy derivative of an antibiotic of the anthracycline group, derived from the bacterium 'streptomyces pneucetus', a kind of soil fungi. DOX is an effective broad-spectrum antibiotic.<sup>1</sup> (Figure 1)




Figure 1. Chemical structure of DOX<sup>1</sup>

## Pharmacokinetics of DOX

Conventional DOX is more distributed in plasma and tissues. Absorption takes place within the cell and binds to cellular components that bind more to nucleic acid in cellular Deoxyribonucleic Acid (DNA). Since it cannot cross the blood-brain barrier, it cannot reach the drug concentration in the cerebrospinal fluid, and its absorption in the brain is slower.<sup>2</sup> DOX is administered intravenously because it is not well absorbed in the gastrointestinal tract.<sup>1</sup> Approximately 4-5 days after DOX administration, the drug and its metabolite are excreted in the urine unchanged due to bile.<sup>3</sup> After DOX administration, it is converted to its active metabolite doxorubicinol using a NADPH-dependent aldo-reductase enzyme. Doxorubicinol is the active ingredient that provides antineoplastic activity. These reductases are found in erythrocytes, kidney and liver cells.<sup>4</sup>

## Mechanism of Action of DOX

After Dox is applied, it begins to act on the cell in 4 ways:<sup>5</sup>

- Binding to DNA by forming a complex structure: The DOX trajectory includes a tendency to undergo DNA base pair coupling, breakage of DNA strands, as well as inhibition of RNA synthesis. DOX inhibits the topoisomerase II enzyme, causing DNA expression and apoptosis. When combined with iron, DOX also causes free radical-mediated oxidative action in DNA, further limiting DNA synthesis. Iron chelators such as dexrazoxane can inhibit liberation by inhibiting DOX by inhibiting it with iron.<sup>6</sup>
- Inhibition of DNA and RNA polymerases: It impairs DNA replication and RNA transcription by inhibiting the functions of DNA and RNA polymerases.
- Effects on the cell membrane: By binding to the cell membrane, it disrupts the membrane function.<sup>7</sup>
- Free radical generation: It reacts with the cytochrome P450 reductase enzyme in the microsomes and forms free oxygen radicals (SOR).<sup>8</sup>

## Cardiotoxicity

"Cardiotoxicity", generally defined as "toxicity affecting the heart"<sup>9</sup> is the most common contraindication of cancer chemotherapy.<sup>10</sup> Advances in treatments in the field of cancer led to the opening of the cardiology chapter.<sup>11</sup> Although it is known to have cardiotoxic potential, many chemotherapeutic drugs are still used in cancer treatment. Since these drugs have positive effects such as completely curing patients or prolonging their survival, they continue to be used despite all these complications.<sup>12</sup> Various mechanisms have been proposed for Dox-induced cardiotoxicity or heart failure. The cardiac complication of DOX is directly related to increased oxidative stress in heart tissue. Increased oxidative stress causes the formation of reactive oxygen

species that damage the heart muscle and occur due to the reduction of antioxidants and sulfur hydryl groups. In addition, Dox-induced cardiotoxicity includes altered Ca<sup>2+</sup> ion levels that cause apoptosis. Apoptosis occurs with the activation of caspases in cardiomyocytes and endothelial cells.<sup>13</sup>

## DOX and Cardiotoxicity

One of the most important side effects of the drug is cardiac toxicity. Although the mechanism of cardiotoxicity caused by DOX is still not clearly understood, some studies prove that oxidative stress plays a vital role in the mechanism of cardiotoxicity. Decreased antioxidant system and increased oxidative stress play an important role in DOX-induced cardiotoxicity. Co-administered drugs may reduce DOX accumulation in the heart.<sup>14</sup> The most important side effect of production of free radicals after DOX administration is cardiac muscle cell damage.<sup>15</sup> DOX-induced cardiotoxicity is manifested through increased production of SOR and lipid peroxidation in cardiac tissues. Iron complexes of aglycones and anthracyclines promote SOR production.<sup>16</sup> Dox metabolite doxorubicinol removes iron from the catalytic Fe-S cluster of cytoplasmic aconitase (also known as iron-regulating protein-1) and converts this enzyme to a nonfunctional protein.<sup>17</sup> A defect in the iron regulatory gene HFE (Human homeostatic iron regulatory protein) leads to increased iron accumulation in the myocardium and causes cardiotoxicity.<sup>18</sup> The HFE gene plays an important role in the regulation of circulating iron intake.<sup>19</sup> In normal body physiology, cardiomyopathy does not occur because levels of free iron content are not sufficient to bind DOX.<sup>20</sup> In addition, DOX reduces long-chain fatty acid oxidation in the mitochondria of the heart and increases glucose metabolism by showing anaerobic metabolism apart from aerobic metabolism. This shift in metabolism can lead to heart failure or abnormal contraction and relaxation; this shift of metabolism occurs solely due to oxidative stress.<sup>21</sup>

## Clinical Types of Cardiotoxicity

DOX cardiotoxicity can develop in four different clinical types:

- Acute Cardiotoxicity: Acute anthracycline cardiotoxicity develops during or within hours of administration of the drug. It presents with electrocardiographic abnormalities, arrhythmias, left ventricular dysfunction, heart failure, and, rarely, myocarditis-pericarditis syndrome, which can be fatal.<sup>22</sup>
- Subacute Cardiotoxicity: It can occur a few days to a few weeks after administration, and can be seen as acute left heart failure, myocarditis and pericarditis.<sup>23</sup>
- Chronic Cardiotoxicity: Late-term toxicity is more common than acute cardiotoxicity in patients receiving anthracycline therapy in the childhood age group and constitutes important health problems. It may develop one to twenty years after completion of treatment. While it may develop in patients who develop and recover from cardiac dysfunction in the subacute period, late-term cardiotoxicity may develop in the long-term follow-up of patients without cardiac involvement in the early period.<sup>24</sup>
- Late Cardiotoxicity: Occurs years after chemotherapy is completed. This particular aspect of anthracycline-induced cardiotoxicity is particularly important for adult survivors of pediatric malignancies.<sup>25</sup> It progresses with late-onset ventricular dysfunction and arrhythmias, and it may rarely result in sudden death. In some patients, the first signs of cardiotoxicity may appear too late.<sup>26</sup>

## Discussion

With the increasing incidence of cancer in recent years, increased doses of antineoplastic drugs and more diverse combinations have been used to provide better toxicity control in these patients.<sup>27</sup> DOX is a chemotherapeutic agent of the anthracycline group used for the destruction of tumors. DOX has the ability to inhibit DNA

biosynthesis by DNA intercalation. This drug has high affinity for sites containing Guanine-Cytosine (GC) base pairs and forming hydrogen bonds between DOX and guanine, causing the formation of triple DOX-DNATopoisomerase II complexes that activate DNA damage responses and eventually cause cell death.<sup>28</sup> Demir et al. evaluated the antioxidant system and lipid peroxidation after the last DOX injection in cardiotoxicity studies induced by DOX, and showed that DOX reduces heart tissue GSH-Px and increases lipid peroxidation products in the chronic process.<sup>29</sup> In recent years, biological markers have been used together with ECHO to detect cardiotoxicity due to anthracyclines. ProBNP and troponin I are two of these markers.<sup>30</sup> Troponin (Troponin-I, Troponin-C), CK-MB and brain natriuretic peptide (BNP) markers are the most important markers used to define cardiac damage and to describe the failure that occurs after this damage. DOX has long been thought to act as a pro-oxidative agent, but a large number of studies, demonstrated that this anticancer drug can induce significant oxidative stress within cells.<sup>31</sup> Free radicals, which are the products of oxidation reactions, cause damage to cells and tissues; Eventually, it causes many chronic diseases such as cardiovascular and cancer.<sup>32</sup> Oxidative damage to membrane lipids and other cellular components is thought to be the major factor in the toxicity of DOX and other anthracyclic antibiotics. For this reason, it has been proven in most studies that the use of natural and artificial antioxidants protects against oxidative stress caused by DOX and other drugs in this derivative.<sup>33</sup> While the use of antioxidants has been shown to play a positive role in the treatment of the most common diseases such as CVD and cancer, studies among healthy people and people with heart disease have shown that antioxidants reduce free radicals and protect LDL against oxidation.<sup>34</sup> Dong et al.<sup>35</sup> reported that quercetin, a powerful antioxidant, suppressed DOX-induced cardiotoxicity. Carino-Cortes et al.<sup>36</sup> reported that naringin, with Daunorubicin, an anticancer agent, prevents DNA damage that starts as a result of oxidative stress in hepatocytes and cardiocytes. In recent years, P.v.L., rich in phenolic compounds, which is a very powerful antioxidant, has been shown to have protective effects against diseases associated with increased oxidative stress as a result of excessive production of free radicals such as cardiovascular diseases (CVD) and cancer.<sup>37</sup> Studies have shown that consumption of green pistachios (P.v.L.) significantly reduces total cholesterol.<sup>38</sup> and LDL.<sup>39</sup> while significantly increasing low-density lipoprotein. In a study on this subject, it was determined that the outer shell of the peanut contains high antioxidants.<sup>40</sup>

## Conclusion

As a result of this research, besides the advantages provided by the therapeutic properties of DOX, the cardiotoxicity caused by its use causes the production of free oxygen radicals. To reduce these effects, the use of natural or artificial antibiotics is needed. Therefore, the discovery of new antibiotics is of great importance.

## Declarations

### Animal and Human Rights Statement

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. No animal or human studies were carried out by the authors for this article.

### Data Availability

The datasets used and/or analyzed during the current study are not publicly available due to patient privacy reasons but are available from the corresponding author on reasonable request.

### Conflict of Interest

None of the authors received any type of financial support that could be considered potential conflict of interest regarding the manuscript or its submission.

## Funding

None.

## Scientific Responsibility Statement

The authors declare that they are responsible for the article's scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.

## References

- Türker A, Kayaalp O. Kanser kemoterapisinin esasları ve antineoplastik ilaçlar (fundamentals of cancer chemotherapy and antineoplastic drugs). In: Kayaalp O, ed. Rasyonel tedavi yönünden tıbbi farmakoloji (medical pharmacology for rational treatment). 10th ed. Ankara: Hacettepe-Taş; 2002:380-415.
- McEvoy GK, ed. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists; 2005:263.
- Polovich M, Whitford JM, Olsen M, eds. Chemotherapy and biotherapy guidelines and recommendations for practice. Pittsburgh, PA: Oncology Nursing Society; 2009:1-4.
- Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. Chemotherapy of neoplastic diseases. In: Hardman JG, Limbird LE, Goodman LS, Gilman A, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001:1426-1428.
- Lipshultz SE, Alvarez JA, Scully RE. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. *Heart*. 2008;94(4):525-533. doi:10.1136/hrt.2007.136093
- Sriharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. *Life Sci*. 2021;278:119527. doi:10.1016/j.lfs.2021.119527
- Hideg K, Kálai T. Novel antioxidants in anthracycline cardiotoxicity. *Cardiovasc Toxicol*. 2007;7(2):160-164. doi:10.1007/s12012-007-0019-z
- Mordente A, Meucci E, Martorana GE, Giardina B, Minotti G. Human heart cytosolic reductases and anthracycline cardiotoxicity. *IUBMB Life*. 2001;52(1-2):83-88. doi:10.1080/1521654025774829
- Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. *J Natl Cancer Inst*. 2010;102(1):14-25. doi:10.1093/jnci/djp440
- Patanè S. Cardiotoxicity: cisplatin and long-term cancer survivors. *Int J Cardiol*. 2014;175(1):201-202. doi:10.1016/j.ijcard.2014.04.238
- Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy: implications for children. *Paediatr Drugs*. 2005;7(3):187-202. doi:10.2165/00148581-200507030-00005
- Vincent DT, Ibrahim YF, Espey MG, Suzuki YJ. The role of antioxidants in the era of cardio-oncology. *Cancer Chemother Pharmacol*. 2013;72(6):1157-1168. doi:10.1007/s00280-013-2260-4
- Octavia Y, Tocchetti CG, Gabrielson KL, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. *J Mol Cell Cardiol*. 2012;52(6):1213-1225. doi:10.1016/j.yjmcc.2012.03.006
- Sun XP, Wan LL, Yang QJ, et al. Scutellarin protects against doxorubicin-induced acute cardiotoxicity and regulates its accumulation in the heart. *Arch Pharm Res*. 2017;875-883. doi:10.1007/s12272-017-0907-0
- Horenstein MS, Vander Heide RS, L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. *Mol Genet Metab*. 2000;71(1-2):436-444. doi:10.1006/mgme.2000.3043
- Simůnek T, Štěrba M, Popelová O, et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. *Pharmacol Rep*. 2009;61(1):154-171.
- Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. *Cancer Res*. 2001;61(23):8422-8428.
- Canzoneri JC, Oyeler AK. Interaction of anthracyclines with iron responsive element mRNAs. *Nucleic Acids Res*. 2008;36(21):6825-6834. doi:10.1093/nar/gkn774
- Barton JC, Bertoli LF. Transfusion iron overload in adults with acute leukemia: manifestations and therapy. *Am J Med Sci*. 2000;319(2):73-78. doi:10.1097/00000441-200002000-00001
- Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol Rev*. 2004;56(2):185-229. doi:10.1124/pr.56.2.6
- Chen Y, Huang T, Shi W, et al. Potential targets for intervention against doxorubicin-induced cardiotoxicity based on genetic studies: a systematic review of the literature. *J Mol Cell Cardiol*. 2020;138:88-98. doi:10.1016/j.yjmcc.2019.11.150
- Bansal N, Amdani S, Lipshultz ER, Lipshultz SE. Chemotherapy-induced cardiotoxicity in children. *Expert Opin Drug Metab Toxicol*. 2017;13(8):817-832. doi:10.1080/17425255.2017.1351547
- Shakir DK, Rasul KI. Chemotherapy-induced cardiomyopathy: pathogenesis, monitoring and management. *J Clin Med Res*. 2009;1(1):8-12. doi:10.4021/jocmr2009.02.1225

24. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. *Cancer Treat Rev.* 2004;30(2):181-191. doi:10.1016/j.ctrv.2003.07.003
25. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: a long-term follow-up study. *J Clin Oncol.* 2001;19(1):191-196. doi:10.1200/jco.2001.19.1.191
26. Singal PK, Li T, Kumar D, et al. Adriamycin-induced heart failure: mechanism and modulation. *Mol Cell Biochem.* 2000;207(1-2):77-86. doi:10.1023/a:1007094214460
27. Demircan Z. Kemoterapi hazırlamada robotik teknolojiler ve hemşirenin rolü (robotic technologies and the role of the nurse in chemotherapy preparation). *Yıldırım Beyazıt Üni Sađ Bilim Fak Hemşirelik E-Derg.* 2014;2(1):36-42.
28. Santos D, Goldenberg R. Doxorubicin-induced cardiotoxicity: from mechanisms to development of efficient therapy. *Cardiotoxicity.* 2018:3-24. doi:10.5772/intechopen.79588
29. Demir F, Narin F, Akgün H, et al. Doksorubisin ile oluşturulmuş deneysel kardiyotoksosite üzerine melatoninin etkisi (effect of melatonin on doxorubicin-induced experimental cardiotoxicity). *Çocuk Sađlığı Hast Derg.* 2004;47:260-268.
30. Liu B, Bai QX, Chen XQ, et al. Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line. *Zhongguo Shi Yan Xue Ye Xue Za Zhi.* 2007;15(4):762-766.
31. Tangpong J, Miriyala S, Noel T, et al. Doxorubicin-induced central nervous system toxicity and protection by xanthone derivatives of *Garcinia mangostana*. *Neuroscience.* 2011;175:292-299. doi:10.1016/j.neuroscience.2010.11.007
32. Köksal E, Gülçin İ. Antioxidant activity of cauliflower (*Brassica oleracea* L.). *Turk J Agric For.* 2008;32:65-78.
33. Kang YJ, Sun X, Chen Y, Zhou Z. Inhibition of doxorubicin chronic toxicity in catalase-over-expressing transgenic mouse hearts. *Chem Res Toxicol.* 2002;15(1):1-6. doi:10.1021/bx015532n
34. Seifried HE, Anderson DE, Fisher EI, Miller JA. A review of the interaction among dietary antioxidants and reactive oxygen species. *J Nutr Biochem.* 2007;18(9):567-579. doi:10.1016/j.jnutbio.2006.10.007
35. Dong Q, Chen L, Lu Q, et al. Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression. *Br J Pharmacol.* 2014;171(19):4440-4454. doi:10.1111/bph.12795
36. Carino-Cortés R, Alvarez-González I, Martino-Roaro L, Madrigal-Bujaidar E. Effect of naringin on the DNA damage induced by daunorubicin in mouse hepatocytes and cardiocytes. *Biol Pharm Bull.* 2010;33(4):697-701.
37. Hassellund SS, Flaa A, Kjeldsen SE, et al. Effects of anthocyanins on cardiovascular risk factors and inflammation in prehypertensive men: a randomized placebo-controlled crossover study. *J Hum Hypertens.* 2013;27(2):100-106. doi:10.1038/jhh.20124
38. Sarı I, Baltacı Y, Bađcı C, et al. Effect of pistachio diet on lipid parameters, endothelial function, inflammation, and oxidative status: a prospective study. *Nutrition.* 2010;26(4):399-404.
39. Kay CD, Gebauer SK, West SG, Kris-Etherton PM. Pistachios increase serum antioxidants and lower serum oxidized LDL in hypercholesterolemic adults. *J Nutr.* 2010;140(6):1093-1098. doi:10.3945/jn.109.117366
40. Zoral FB, Turgay Ö. Çeşitli gıda atıklarının toplam fenolik madde içeriğinin, antioksidan ve antimikrobiyal aktivitelerinin araştırılması (investigation of total phenolic content, antioxidant and antimicrobial activities of various food wastes). *KSÜ Dođa Bil Derg.* 2014;17(2):24-33. doi:10.18016/ksujns.03907